INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Biomea Fusion, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: BMEA)
NEW YORK, July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biomea Fusion, Inc.:
On June 23, 2023, Biomea Fusion presented data for its Type 2 diabetes drug candidate BMF-219 at a meeting of the American Diabetes Association. In response to the presentation, market analysts downgraded Biomea Fusion and its stock price fell $6.25 per share, from $30.67 per share on June 23, 2023 to close at $24.42 per share on June 26, 2023.
Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Biomea Fusion investors. If you incurred a loss on your BMEA investment, please contact us using the link below to discuss your rights.
https://securitiesclasslaw.com/securities/biomea-fusion-loss-submission-form/?id=41986&from=4
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
SOURCE The Gross Law Firm
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article